High doses of tigecycline are associated with satisfactory plasmatic and pulmonary concentrations for the treatment of severe infections due to fully susceptible bacteria: do we need even higher doses in patients under CRRT?

Detalles Bibliográficos
Autores principales: Honore, Patrick M., Barreto Gutierrez, Leonel, Kugener, Luc, Redant, Sebastien, Attou, Rachid, Gallerani, Andrea, De Bels, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7560687/
https://www.ncbi.nlm.nih.gov/pubmed/33052490
http://dx.doi.org/10.1186/s13613-020-00758-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7560687/
https://www.ncbi.nlm.nih.gov/pubmed/33052490
http://dx.doi.org/10.1186/s13613-020-00758-5

Ejemplares similares